Targeting Tumor-Associated Macrophages by MMP2-Sensitive Apoptotic Body-Mimicking Nanoparticles.
Animals
Antineoplastic Agents
/ chemistry
Apoptosis
/ drug effects
Cell Line, Tumor
Dasatinib
/ chemistry
Female
Humans
Larva
/ metabolism
Matrix Metalloproteinase 2
/ metabolism
Mice
Mice, Inbred BALB C
Nanoparticles
/ chemistry
Neoplasms
/ drug therapy
Phagocytosis
Phosphatidylserines
/ chemistry
Polyethylene Glycols
/ chemistry
RAW 264.7 Cells
Tissue Distribution
Tumor-Associated Macrophages
/ cytology
Zebrafish
/ growth & development
apoptotic body
drug delivery
matrix metalloproteinase 2
nanoparticles
phosphatidylserine
tumor-associated macrophages
Journal
ACS applied materials & interfaces
ISSN: 1944-8252
Titre abrégé: ACS Appl Mater Interfaces
Pays: United States
ID NLM: 101504991
Informations de publication
Date de publication:
25 Nov 2020
25 Nov 2020
Historique:
pubmed:
11
11
2020
medline:
26
2
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
Tumor-associated macrophages (TAMs), a major player in the tumor microenvironment, were recently recognized as a potential therapeutic target. To date, very few anticancer drugs or drug-delivery systems were designed to target the TAMs. Inspired by the "eat me" signal, phosphatidylserine (PS), mediated phagocytic clearance of apoptotic bodies, in this study, the matrix metalloproteinase 2 (MMP2)-sensitive PS-modified nanoparticles were developed. In the design, the PS is externalized to the nanoparticles' surface only when the nanoparticles reach the MMP2-overexpressing tumor site, allowing for the TAM-specific phagocytosis. The nanoparticles' excellent macrophage/TAM selectivity was observed in various biological models, including various cell lines, coculture cells, coculture cell spheroids, zebrafish, and tumor-bearing mice. The nanoparticles' TAM specificity remarkably enhanced the TAM depletion capability of the loaded model drug, dasatinib, resulting in the improved anticancer activity. The MMP2-sensitive apoptotic body-mimicking nanoparticles might be a promising delivery tool for TAM-centered cancer diagnoses and treatments.
Identifiants
pubmed: 33169982
doi: 10.1021/acsami.0c15983
pmc: PMC8229024
mid: NIHMS1714507
doi:
Substances chimiques
Antineoplastic Agents
0
Phosphatidylserines
0
Polyethylene Glycols
3WJQ0SDW1A
Matrix Metalloproteinase 2
EC 3.4.24.24
Dasatinib
RBZ1571X5H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52402-52414Subventions
Organisme : NCI NIH HHS
ID : R15 CA213103
Pays : United States
Références
ACS Nano. 2012 Apr 24;6(4):3491-8
pubmed: 22409425
Nat Rev Drug Discov. 2014 Dec;13(12):904-27
pubmed: 25376097
J Biol Chem. 1993 Feb 15;268(5):3530-7
pubmed: 8429029
Cancer Res. 2015 Oct 1;75(19):4063-73
pubmed: 26238785
J Clin Invest. 2016 Nov 1;126(11):4157-4173
pubmed: 27721235
Methods Mol Biol. 2008;440:15-33
pubmed: 18369934
Int J Oncol. 2000 Oct;17(4):673-81
pubmed: 10995877
J Control Release. 2014 Jun 10;183:114-23
pubmed: 24698945
Br J Pharmacol. 2007 Jul;151(6):844-50
pubmed: 17533418
Cancer Immunol Res. 2017 Feb;5(2):157-169
pubmed: 28073775
J Immunol. 2003 May 1;170(9):4840-5
pubmed: 12707367
Biomaterials. 2011 May;32(13):3435-46
pubmed: 21295849
Nanomedicine. 2019 Jul;19:71-80
pubmed: 31004812
J Cell Biol. 2001 Nov 12;155(4):649-59
pubmed: 11706053
Chem Commun (Camb). 2019 Apr 4;55(29):4254-4257
pubmed: 30901007
J Control Release. 2015 Aug 28;212:94-102
pubmed: 26113423
Free Radic Biol Med. 2007 Apr 1;42(7):945-54
pubmed: 17349923
Clin Cancer Res. 2001 Aug;7(8):2396-404
pubmed: 11489818
Trends Pharmacol Sci. 2018 Aug;39(8):766-781
pubmed: 30032745
Cell. 2010 Apr 2;141(1):52-67
pubmed: 20371345
Nat Rev Drug Discov. 2005 Jan;4(1):35-44
pubmed: 15688071
Pathol Res Pract. 2011 Dec 15;207(12):747-53
pubmed: 22030137
Curr Biol. 2006 Nov 7;16(21):2156-60
pubmed: 17084701
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):475-9
pubmed: 1302560
J Clin Invest. 2006 Aug;116(8):2132-2141
pubmed: 16862213
J Biomed Nanotechnol. 2016 Jun;12(6):1199-210
pubmed: 27319214
Cell Rep. 2016 May 31;15(9):2000-11
pubmed: 27210762
Am J Pathol. 1993 Nov;143(5):1406-15
pubmed: 8238256
ACS Appl Mater Interfaces. 2017 Oct 25;9(42):36642-36654
pubmed: 28960955
Nature. 1974 Aug 23;250(5468):667-9
pubmed: 4546859
ACS Appl Mater Interfaces. 2017 Nov 22;9(46):39971-39984
pubmed: 29076344
Nano Today. 2015 Aug;10(4):487-510
pubmed: 26640510
Cancer Lett. 2004 Aug 10;211(2):235-42
pubmed: 15219947
Eur J Cancer. 2003 Sep;39(13):1948-56
pubmed: 12932675
Cancer Cell. 2011 Jan 18;19(1):31-44
pubmed: 21215706
Mol Ther. 2005 Sep;12(3):468-74
pubmed: 15963763
Cell Biochem Biophys. 2014 Jan;68(1):143-52
pubmed: 23812723
J Immunol. 2004 Dec 1;173(11):6973-80
pubmed: 15557194
Int J Cancer. 2006 Sep 15;119(6):1403-11
pubmed: 16615109
ACS Appl Mater Interfaces. 2016 May 25;8(20):12661-73
pubmed: 27145021
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
Cell. 1996 May 31;85(5):683-93
pubmed: 8646777
Biochim Biophys Acta. 2010 Jan;1803(1):103-20
pubmed: 19800930
J Biol Chem. 1995 Jul 21;270(29):17250-6
pubmed: 7615524
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Clin Cancer Res. 2011 Sep 15;17(18):6061-70
pubmed: 21810917
Oncotarget. 2017 Jun 27;8(26):41827-41840
pubmed: 28611279
Biomaterials. 2015 Oct;67:104-14
pubmed: 26210177
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17047-52
pubmed: 24062440
Immunity. 2014 Jul 17;41(1):49-61
pubmed: 25035953
Br J Cancer. 2006 Aug 7;95(3):272-81
pubmed: 16832418
ACS Nano. 2014 Jul 22;8(7):7014-26
pubmed: 24945994
Blood. 2012 Nov 29;120(23):4533-43
pubmed: 22936666
Leukemia. 2009 Mar;23(3):590-4
pubmed: 18784745
J Lipid Res. 2009 Nov;50(11):2157-63
pubmed: 19017616
ACS Appl Mater Interfaces. 2017 Sep 27;9(38):32520-32533
pubmed: 28870072
Br J Pharmacol. 2008 Aug;154(7):1400-13
pubmed: 18552866